Tag - TROV

Developments

Trovagene reports positive ovansertib data from Phase 2 prostate cancer trial

Trovagene (NASDAQ:TROV) reported new positive data from its Phase 2 trial of onvansertib in combination with Zytiga in patients with metastatic castration-resistant prostate cancer (mCRPC). The study’s primary efficacy...

November 14, 2019

Developments

Trovagene AML drug generates positive interim Phase 1b/2 data

Trovagene (NASDAQ:TROV) announced positive interim data from its Phase 1b/2 dose escalation trial of onvansertib, in combination with standard-of-care chemotherapy, in acute myeloid leukemia (AML) patients. Three of six...

April 5, 2019

Tag - TROV

Trovagene reports positive ovansertib data from Phase 2 prostate cancer trial

Trovagene AML drug generates positive interim Phase 1b/2 data

General

More